CFFP
VRTX icon

Center for Financial Planning’s Vertex Pharmaceuticals VRTX Stock Holding History

Center for Financial Planning’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-50
Closed -$22.7K – 728
2025
Q4 		$22.7K Hold
50
– – ﹤0.01% 399
2025
Q3 		$19.6K Hold
50
– – ﹤0.01% 417
2025
Q2 		$22.3K Sell
50
-17
-25% -$7.83K ﹤0.01% 384
2025
Q1 		$32.5K Hold
67
– – ﹤0.01% 335
2024
Q4 		$27K Buy
67
+17
+34% +$7.88K ﹤0.01% 319
2024
Q3 		$23.3K Hold
50
– – ﹤0.01% 323
2024
Q2 		$23.4K Hold
50
– – ﹤0.01% 307
2024
Q1 		$20.9K Buy
+50
New +$21.1K ﹤0.01% 322
2021
Q2 		– Sell
-59
Closed -$13K – 545
2021
Q1 		$13K Hold
59
– – ﹤0.01% 358
2020
Q4 		$14K Sell
59
-50
-46% -$11.5K ﹤0.01% 315
2020
Q3 		$30K Sell
109
-50
-31% -$13.8K 0.01% 225
2020
Q2 		$46K Buy
159
+100
+169% +$27.1K 0.02% 192
2020
Q1 		$14K Hold
59
– – ﹤0.01% 292
2019
Q4 		$13K Buy
+59
New +$11.9K ﹤0.01% 292

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Center for Financial Planning's VRTX Position: Q1 2026 in Review

Center for Financial Planning sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 50 shares — an estimated $22.7K sold.

Center for Financial Planning first reported a position in VRTX in Q4 2019 and held it in 14 quarters. The position peaked at $46K in Q2 2020. 1,695 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Center for Financial Planning reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Center for Financial Planning sold 50 Vertex Pharmaceuticals shares in Q1 2026, an estimated $22.7K.
  • Center for Financial Planning first reported a position in Vertex Pharmaceuticals in Q4 2019 and held it in 14 quarters.
  • Center for Financial Planning's Vertex Pharmaceuticals position peaked at $46K in Q2 2020.
  • 1,695 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Center for Financial Planning's 13F filing for Q1 2026, filed 4 May 2026.